Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care populationRESPIRATORY MEDICINEIF3.12018-12-0145OAAI
Validation of the Nontuberculous Mycobacteria (NTM) Module in NTM Lung DiseaseEUROPEAN RESPIRATORY JOURNALIF212018-11-191PRE
ALL-CAUSE MORTALITY INCREASED WITH NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN US MEDICAREVALUE IN HEALTHIF62018-10-010OAAI
INCIDENCE AND PREVALENCE OF NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN US MEDICARE, 2008-2015VALUE IN HEALTHIF62018-10-010OAAI
RISK FACTORS AND DIAGNOSIS OF NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE (NTMLD) IN INCIDENT COHORTS OF BRONCHIECTASIS (BE) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A NATIONAL US MANAGED CARE INSURANCE PLANVALUE IN HEALTHIF62017-10-010OAAI
HEALTHCARE INSURANCE SPENDING AT YEAR 2 BETWEEN TREATMENT GROUPS FOLLOWING DIAGNOSIS OF NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN THE USVALUE IN HEALTHIF62017-10-010PREAI
UTILISATION PATTERN OF GLP-1 AGONISTS IN COMBINATION WITH BASAL INSULIN IN PATIENTS WITH T2DM IN THE NORWEGIAN SETTING IN ONE YEARVALUE IN HEALTHIF62013-11-010PREAI